U091 Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy
DESCRIPTION
Update on the latest cancer therapies and dermatologists' role in managing cutaneous toxicities. This year the focus is on toxicities to MAPk pathway inhibitors and enfortumab vedotin as well as advanced management of severe immune checkpoint inhibitor induced toxicities with a focus on mucosal disease. This activity has been approved by the American Board of Dermatology (ABD) for up to 10 Continuing Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Review trends in cancer therapy and the resulting cutaneous toxicities.
Discuss challenging diagnostic scenarios.
Discuss challenging management scenarios and management algorithms.
SCHEDULE
7:30 AM
Updates in Targeted Inhibitor- Induced Toxicities
Anisha Patel, MD, FAAD
7:55 AM
Updates in Checkpoint Inhibitor- Induced Toxicities
Meghan M. Heberton, MD, FAAD
8:20 AM
Q & A
DIRECTOR
Anisha Patel, MD, FAAD
SPEAKER
Meghan M. Heberton, MD, FAAD
HANDOUTS
DISCLOSURES
Meghan M. Heberton, MD, FAAD
Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Blueprint Medicines – Advisory Board(Fees); Revolution Medicines – Advisory Board(Fees);
Anisha Patel, MD, FAAD
Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Deciphera Pharmaceuticals, Inc. – Consultant (1099 relationship)(Fees); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); FBIO Acquisition Corp LXI – Consultant (1099 relationship)(Stock); Hoth Therapeutics – Investigator(Grants/Research Funding); IDEOlogy Health – Consultant (1099 relationship)(Fees); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);